Gov. Christopher J. Christie serves as Director of the Company. He has been a Managing Member of Christie 55 Solutions, LLC ("Christie LLC"), a consulting firm that assists corporate, government and association clients with their business strategies and complex public policy and regulatory challenges at the state, federal and international levels, since March 2018. Previously, he was Governor of the State of New Jersey from January 2010 until January 2018. Governor Christie holds a B.A. in political science from the University of Delaware and earned his J.D. from Seton Hall University School of Law. Governor Christie is also a recipient of Honorary Doctoral degrees from Rutgers University, University of Delaware, Seton Hall University, Monmouth University and Centenary College.
As the Director of Pacira BioSciences Inc, the total compensation of Christopher Christie at Pacira BioSciences Inc is 901,503$. There are 8 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of 5,806,430$.
Christopher Christie is 57, he's been the Director of Pacira BioSciences Inc since 2019. There are 14 older and 10 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Christopher's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over 321,391,130$ worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth 15,133,188$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、Carl L Gordon、Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of 491,036$. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth 20,034$.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: